OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$7.88 USD
+0.02 (0.25%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.89 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
OPRX 7.88 +0.02(0.25%)
Will OPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPRX
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
OptimizeRx Corp. (OPRX) Tops Q2 Earnings Estimates
OPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
NuScale Power (SMR) to Post Q2 Earnings: What's in Store?
DigitalOcean (DOCN) to Post Q2 Earnings: What's in Store?
Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue Estimates
Other News for OPRX
OptimizeRx continues to expand strategic relationship with pharma client
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
OptimizeRx price target lowered by $3 at RBC Capital, here's why
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), OmniAb (OABI) and Syndax Pharmaceuticals (SNDX)